TIZIANA LIFE SCIENCES LTD

NASDAQ: TLSA (Tiziana Life Sciences Ltd)

Kemas kini terakhir: semalam, 8:09AM

1.74

-0.03 (-1.69%)

Penutupan Terdahulu 1.77
Buka 1.74
Jumlah Dagangan 156,887
Purata Dagangan (3B) 332,187
Modal Pasaran 206,753,776
Harga / Buku (P/B) 22.99
Julat 52 Minggu
0.630 (-63%) — 2.60 (49%)
Tarikh Pendapatan 23 Jun 2025 - 8 Jul 2025
EPS Cair (TTM) -0.110
Jumlah Hutang/Ekuiti (D/E MRQ) 2.69%
Nisbah Semasa (MRQ) 1.02
Aliran Tunai Operasi (OCF TTM) -1.53 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -8.99 M
Pulangan Atas Aset (ROA TTM) -84.13%
Pulangan Atas Ekuiti (ROE TTM) -250.49%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Tiziana Life Sciences Ltd Bercampur Bercampur

AISkor Stockmoo

-0.9
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal -2.5
Osilator Teknikal -2.0
Purata -0.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TLSA 207 M - - 22.99
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 43.06%
% Dimiliki oleh Institusi 2.73%

Pemilikan

Nama Tarikh Syer Dipegang
Dauntless Investment Group, Llc 30 Sep 2025 2,735,933
Ewa, Llc 30 Sep 2025 46,050
Tarikh Jenis Butiran
02 Dec 2025 Pengumuman Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
02 Dec 2025 Pengumuman Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
25 Nov 2025 Pengumuman Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
25 Nov 2025 Pengumuman Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
13 Nov 2025 Pengumuman Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
13 Nov 2025 Pengumuman Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
29 Oct 2025 Pengumuman Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
29 Oct 2025 Pengumuman Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
30 Sep 2025 Pengumuman Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
30 Sep 2025 Pengumuman Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
25 Sep 2025 Pengumuman Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
25 Sep 2025 Pengumuman Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
24 Sep 2025 Pengumuman Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
24 Sep 2025 Pengumuman Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
15 Sep 2025 Pengumuman Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
15 Sep 2025 Pengumuman Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
09 Sep 2025 Pengumuman Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Pengumuman Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Pengumuman Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 Pengumuman Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda